Search

everythinglearnresearchcommunity

for

Search:↓

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

The conversation is about the potential side effects of using verteporfin in conjunction with a hair transplant. Specific treatments discussed include verteporfin, a hair transplant (HT), minoxidil (Min), finasteride (Fin), and RU58841 (RU).

A 27-year-old man shared his hair regrowth progress after using finasteride for 4 years, recently adding a solution of RU58841 with minoxidil and alfatradiol, tretinoin on temples, and occasional ketoconazole. He is seeking opinions on his treatment approach.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

The user is experiencing severe hair loss after starting Minoxidil 5% and is seeking advice, as their hair loss worsened following a second COVID infection. Despite normal hormone and vitamin levels, the user is considering additional treatments like Ketoconazole shampoo, massages, and low-level laser therapy.

Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.

A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

The conversation is about the effectiveness of topical melatonin for hair loss. No specific treatments were discussed, only a sarcastic suggestion to go to tropical places and eat coconuts.

The user experienced prolonged hair shedding after restarting oral minoxidil (OM) at 2.5 mg in September 2023, following a break due to hypertrichosis. Despite seeing regrowth, the shedding has not decreased after 11 weeks on the increased dosage.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

The conversation is about sourcing Latanoprost for hair loss treatment. Users discuss potential sources and the difficulty of obtaining a prescription.

The user experienced significant hair shedding and dryness after starting minoxidil 8 months post-hair transplant, despite using finasteride and oils like castor and pumpkin seed oil. They expressed concern over the loss of density and the appearance of a failed transplant.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

A user initially had side effects from finasteride, attributed them to anxiety and the nocebo effect, and after resuming the drug, experienced positive effects and now warns against misinformation about Post Finasteride Syndrome.

The conversation discusses using Botox to treat male pattern baldness, suggesting it may promote hair growth by increasing scalp blood flow and oxygen, reducing dihydrotestosterone levels. The user wonders why this treatment is not widely discussed or if it has been discredited.

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.